Cost Estimation of Point of Care B-Type Natriuretic Peptide for the Diagnosis of Heart Failure in the Emergency Department - Application to Alberta

Alberta Heritage Foundation for Medical Research (AHFMR) Information Paper #25.

The aim of this report is to provide a cost estimate, over a one year time period from a payer’s perspective, of Biosite Triage Point-of-Care (POC) B-Type Natriuretic Peptide (BNP) assay used to rule out congestive heart failure (CHF) from other pulmonary conditions for patients presenting in Alberta emergency departments with acute dyspnea, but who do not have acute mycardial infarction (AMI), renal dysfunction (RD), or unstable angina (UA). The scope of this report is limited to the use of BNP for diagnosis and does not address prognosis, management, or patient monitoring.

Information Specialist: Seana Collins

NOTE: In 2006 the Alberta Heritage Foundation for Medical Research HTA unit moved to IHE. Documents produced in and prior to 2006 have different formats; the format was determined by the agency for which the document was produced.